{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001763950","name":"Lantern Pharma Inc.","summary":"Lantern Pharma Inc. is an AI-focused oncology company developing cancer therapies using its proprietary RADR platform, which contains over 200 billion data points and 200+ machine learning algorithms. Its pipeline includes three clinical-stage small molecule drug candidates (LP-300, LP-184, LP-284) and a preclinical ADC program. The company uses biomarker-driven, genomically-targeted approaches to rescue previously failed drug candidates and develop new compounds, advancing programs from AI insights to first-in-human trials in 2-3 years at approximately $1-2.5 million per program.","people":[],"products":[{"name":"RADR","type":"platform","description":"Proprietary AI platform with 200+ billion oncology data points and 200+ machine learning algorithms for genomic signature discovery and patient stratification."},{"name":"withZeta.ai","type":"platform","description":"Generative AI platform with multi-agentic architecture for rare cancer research and drug development, introduced January 2026."},{"name":"LP-300","type":"service","description":"Clinical-stage small molecule drug candidate in Phase 2 Harmonic trial for never-smoking NSCLC patients in combination with chemotherapy."},{"name":"LP-184","type":"service","description":"Clinical-stage small molecule with Phase 1a completed; Phase 1b/2 trials planned for TNBC, NSCLC, and CNS/brain cancers including GBM."},{"name":"LP-284","type":"service","description":"Clinical-stage small molecule in Phase 1a trial targeting hematological cancers."},{"name":"LP-100","type":"service","description":"Small molecule drug candidate with potential for development in combination with PARP inhibitors; Phase 2 trial in Denmark closed in Q1 2023."},{"name":"ADC Program","type":"service","description":"Preclinical antibody-drug conjugate program using AI-powered module and cryptophycin payloads for multiple solid tumor indications."},{"name":"Starlight Therapeutics","type":"service","description":"Wholly-owned subsidiary focused on clinical development of LP-184 (also called STAR-001) for CNS and brain cancer indications."}],"partnerships":[{"partner_name":"Bielefeld University","partnership_type":"development","description":"Research collaboration focused on ADC development utilizing cryptophycin as drug-payload, initiated in 2023.","start_date":null},{"partner_name":"Allarity Therapeutics A/S","partnership_type":"licensing","description":"LP-100 was previously out-licensed to Allarity; Lantern reacquired global rights via Asset Purchase Agreement in July 2021.","start_date":null}],"affiliations":[],"origin":{"leaf":"0f0de39e5606d28e7fa419c3923c2dac584aa9e802aedc6406cdeee316d301fb","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"d00cfaf64c2d15c53fa64406c75283b7f575bad1139dfe4a4af05eb4d04e90af","parent":"647db3821d525bf4ef89561f9a777924649c519157921134a3db61294d40ad91","source":"0001493152-26-013612","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":340,"hourly_limit":500,"remaining":160,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}